Our study provides functional evidence that metabolic reprogramming can directly impact cancer phenotypes and establishes proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)-induced mitochondrial metabolism as a driver of small cell neuroendocrine cancer (SCNC) progression and lineage determination. Here, PPARGC1A is linked to cancer.